On November 15, 2018, we are joining with our global counterparts in recognizing World Pancreatic Cancer Day to help raise awareness for the catastrophic disease that is pancreatic cancer.
This year, we’re rallying behind an innovative event taking place at Fenway Park in Boston.
Immunovia, a leading company in bioinformatic-assisted diagnostics, is celebrating World Pancreatic Cancer Day 2018 by hosting an educational seminar at the Royal Rooters Club at Fenway Park in Boston. The purpose of this event is to create awareness around early detection of Pancreatic Cancer in the primary care setting where the subtle signs are often unknown. However, We Believe primary care physicians can change the game and intercept and sideline Pancreatic Cancer.
Cathy Griffith had the opportunity to meet with Sweden’s Immunovia team at the Inaugural May 2016 World Pancreatic Cancer Coalition meeting in Miami, FL. (Pictured above from left to right are Mats Grahn – CEO, Immunovia; Cathy Griffith – President, Griffith Family Foundation/Sideline Cancer; Dr. Carl Borrebaeck – Professor and Deputy Vice-Chancellor, Lund University; Rolf Ehrnstrom – Chief Scientific Officer, Immunovia.)
Based in Marlborough, MA, Cindy Callahan, is the Market Access Director for Immunovia, Inc. and the coordinator/organizer and inspiration behind this event.
The parent company, Immunovia AB was founded in 2007 by researchers from the Department of Immunotechnology at Lund University and CREATE Health (the Center for Translational Cancer Research) in Lund, Sweden.
Immunovia’s unique technology platform – IMMray® – combines an antibody-based multiplex with cutting-edge bioinformatics to find the most clinically relevant changes that appear in the blood, and then synthesizes this knowledge into a “disease fingerprint” – also called a biomarker signature.
The IMMray PanCan-d test, Immunovia’s first diagnostic test, is a unique blood test for the early detection of pancreatic cancer. Retrospective studies show that the test is able to detect stage I and stage II pancreatic cancer with an accuracy of 96%. The company is currently performing clinical validation studies for the commercialization of IMMray PanCan-d.
Improving outcomes in pancreatic cancer is a personal passion for Cindy after losing her mother to pancreatic cancer in December 2014. Since her death, Cindy has dedicated her personal and professional time to fundraising for research and creating awareness for early detection.
Fenway Park is also where “The Game” between Harvard and Yale is taking place this year. On November 15th, Fenway will be transformed into a football field in preparation for “The Game” on November 17th, just two days after World Pancreatic Cancer Day.
In keeping with the Harvard/Yale Game rivalry, Immunovia thought it would be apropos to have Harvard/Yale speakers present on what’s currently being done to improve Pancreatic Cancer patient outcomes.
The seminar is titled “Intercepting Pancreatic Cancer: PCPs Can Change the Game.”
Dr. James Farrell
Dr. A. James Moser
Dr. James Farrell, Director of the Yale Center for Pancreatic Diseases at Yale New Haven Hospital and Professor of Medicine at Yale School of Medicine, and Dr. A. James Moser, Co-Director of the Pancreas and Liver Institute at Beth Israel Deaconess Medical Center and Associate Professor of Surgery at Harvard Medical School will be the featured presenters. Both will be providing perspectives on the role early detection can have on improving survival rates.
Also presenting will be Patient Advocate Brigitte Régnier, Board Member, Alliance of Families Fighting Pancreatic Cancer.
Believe Always that United WE Can Sideline Pancreatic Cancer!